Breast cancer immunotherapy: Realities and advances

Cancer Innovation Pub Date : 2024-09-22 DOI:10.1002/cai2.140
Aixa Medina, Jeismar Carballo, Eglys González-Marcano, Isaac Blanca, Ana F. Convit
{"title":"Breast cancer immunotherapy: Realities and advances","authors":"Aixa Medina,&nbsp;Jeismar Carballo,&nbsp;Eglys González-Marcano,&nbsp;Isaac Blanca,&nbsp;Ana F. Convit","doi":"10.1002/cai2.140","DOIUrl":null,"url":null,"abstract":"<p>Breast cancer (BC) is the most common malignant tumor and the main cause of death in women worldwide. With increased knowledge regarding tumor escape mechanisms and advances in immunology, many new antitumor strategies such as nonspecific immunotherapies, monoclonal antibodies, anticancer vaccines, and oncolytic viruses, among others, make immunotherapy a promising approach for the treatment of BC. However, these approaches still require meticulous assessment and readjustment as resistance and modest response rates remain important barriers. In this article, we aim to summarize the most recent data available in BC immunotherapy to include the results of ongoing clinical trials and approved therapies used as monotherapies or in combination with conventional treatments.</p>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"3 5","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.140","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Innovation","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cai2.140","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Breast cancer (BC) is the most common malignant tumor and the main cause of death in women worldwide. With increased knowledge regarding tumor escape mechanisms and advances in immunology, many new antitumor strategies such as nonspecific immunotherapies, monoclonal antibodies, anticancer vaccines, and oncolytic viruses, among others, make immunotherapy a promising approach for the treatment of BC. However, these approaches still require meticulous assessment and readjustment as resistance and modest response rates remain important barriers. In this article, we aim to summarize the most recent data available in BC immunotherapy to include the results of ongoing clinical trials and approved therapies used as monotherapies or in combination with conventional treatments.

Abstract Image

乳腺癌免疫疗法:现实与进步
乳腺癌(BC)是最常见的恶性肿瘤,也是全球女性的主要死因。随着对肿瘤逃逸机制认识的加深和免疫学的进步,许多新的抗肿瘤策略,如非特异性免疫疗法、单克隆抗体、抗癌疫苗和溶瘤病毒等,使免疫疗法成为治疗乳腺癌的一种前景广阔的方法。然而,这些方法仍然需要细致的评估和重新调整,因为耐药性和反应率不高仍然是重要的障碍。在本文中,我们将总结BC免疫疗法的最新数据,包括正在进行的临床试验结果和已获批准的作为单一疗法或与传统疗法联合使用的疗法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.70
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信